You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 137 No. 12, December 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Evidence-Based Dermatology: Research Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Quality of Care
 •Evidence-Based Medicine
 •Randomized Controlled Trial
 •Dermatology, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Placebo Effect: And Another One Bites the Dust

Arch Dermatol. 2001;137:1639-1640.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Is the Placebo Powerless? An Analysis of Clinical Trials Comparing Placebo With No Treatment
Hrobjartsson A, Gotzsche PC
N Engl J Med.
2000;344:1594-1602

Placebo treatments have been reported to help patients with many diseases, but the quality of the evidence supporting this finding has not been rigorously evaluated. The objective of Hrobjartsson and Gotzsche's study was to conduct a meta-analysis of clinical trials in which patients were randomly assigned to either treatment with placebo or no treatment. A placebo could be pharmacological (eg, a tablet), physical (eg, a manipulation), or psychological (eg, a conversation). They systematically searched MEDLINE, EMBASE, PsychLIT, Biological Abstracts, and the Cochrane Controlled Trials Register for trials published before the end of 1998. They included only trials with concealed random assignment, masked outcome assessment, and dropout rates of less than 50%. For each trial with binary outcomes (eg, stroke or no stroke), they calculated the relative risk . . . [Full Text of this Article]

Editor's Comment



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.